Alnylam Pharmaceuticals, Inc.
Market Cap
$41.29B
P/E Ratio
133.40
EPS
$2.32
Dividend Yield
0.00%
52-Week Range
$245.96 — $495.55
Volume
2.19M
Avg Volume
1.25M
Beta
0.38
Get alerted when ALNY hits your target price.
Free — enter your email to get started
P/E (TTM)
133.40
Forward P/E
45.23
PEG Ratio
0.10
P/S (TTM)
10.82
P/B (TTM)
50.47
P/FCF
191.52
EV/EBITDA
206.02x
EV/Sales
—
ROE (TTM)
0.90%
ROA (TTM)
0.06%
ROIC
0.11%
Gross Margin
0.82%
Operating Margin
0.14%
Net Margin
0.20%
Debt/Equity
1.62
Current Ratio
2.76
EPS Growth (YoY)
+3.20%
Revenue Growth (YoY)
+1.44%
EPS Growth (3Y)
+1.03%
EPS Growth (5Y)
+0.57%
Sales Growth (3Y)
+0.55%
Sales Growth (5Y)
+0.52%
EPS Est (This Year)
$6.84
EPS Est (Next Year)
$10.84
Dividend Yield
—
Annual Dividend
—
Payout Ratio
0.00%
Frequency
—
Ex-Dividend Date
—
Cash/Share
$22.00
Buy
1 = Strong Buy, 5 = Strong Sell
Price Target Range
Consensus Target: $460.50(48.8% upside)
Institutional %
—
Inst. Net Change
—
Insider Net Shares (90d)
—
Outstanding Shares
132.62M
Float
131.46M
Free Float %
99.12%
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
NASDAQ
IPO Date
2004-06-01
Employees
2230
CEO
Yvonne L. Greenstreet
Index Membership
—
Website
https://www.alnylam.com
Alnylam Pharmaceuticals, Inc. (ALNY) is a healthcare company in the biotechnology industry listed on the NASDAQ. With a market capitalization of $41.29B, a P/E ratio of 133.40, ALNY is tracked by stockscreenr alongside 25,000+ other tickers. Use the free stock screener to compare ALNY against other stocks using dozens of fundamental and technical filters.
Alnylam Pharmaceuticals, Inc. (ALNY) has a trailing twelve-month (TTM) P/E ratio of 133.40. This is above the market average, which may reflect high growth expectations or premium valuation. The P/E ratio measures how much investors are willing to pay per dollar of earnings.
No, Alnylam Pharmaceuticals, Inc. (ALNY) does not currently pay a regular dividend. The company may be reinvesting profits into growth, research, or debt reduction instead of returning cash to shareholders through dividends.
Alnylam Pharmaceuticals, Inc. (ALNY) has a market capitalization of $41.29 billion, classifying it as a large-cap company. Market cap is calculated by multiplying the current share price by the total number of outstanding shares.
Wall Street analysts have a consensus "Buy" rating on Alnylam Pharmaceuticals, Inc. (ALNY) with an average score of 1.67 on a 1-5 scale (1 = Strong Buy, 5 = Strong Sell). The consensus price target of $460.50 implies 48.8% upside from the current price.